PMID- 19344957
OWN - NLM
STAT- MEDLINE
DCOM- 20090706
LR  - 20211203
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 210
IP  - 1-2
DP  - 2009 May 29
TI  - Combined treatment with minocycline and prednisone attenuates experimental 
      autoimmune encephalomyelitis in C57 BL/6 mice.
PG  - 22-9
LID - 10.1016/j.jneuroim.2009.02.016 [doi]
AB  - There has been enormous progress in the treatment of multiple sclerosis (MS) in 
      recent years, but further improvement in therapy is still required because not 
      all patients respond optimally to existing treatments. Increasing evidence has 
      demonstrated that combination therapies produce a more favorable clinical outcome 
      than monotherapy in MS treatment. Minocycline is effective in experimental 
      autoimmune encephalomyelitis (EAE), and is a promising candidate for future MS 
      medication. Glucocorticosteroids (GCS) belong to the most potent 
      immunosuppressive drugs and are the mainstay for treatment of acute relapses in 
      MS. In this study, we tested whether the combination of minocycline and 
      prednisone (a synthetic GCS) at suboptimal doses could produce synergistic 
      effects in EAE. Our findings showed that the combination of these two drugs 
      functioned better than when they were individually administered in EAE mice, as 
      evidenced by decreased clinical scores, reduced inflammation and demyelination, 
      and improved magnetic resonance imaging outcomes. Further studies revealed that 
      the combined treatment prevented the reduction of brain-derived neurotrophic 
      factor (BDNF) and nerve growth factor (NGF) mRNA expression in cerebral cortex of 
      EAE mice. In conclusion, our findings indicated that this combination therapy 
      suppressed disease severity of EAE partially through blocking the downregulation 
      of neurotrophic factor expression, suggesting that the combination of minocycline 
      and prednisone could be a novel treatment in MS.
FAU - Chen, Xiaohong
AU  - Chen X
AD  - Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Hu, Xueqiang
AU  - Hu X
FAU - Zou, Yan
AU  - Zou Y
FAU - Pi, Rongbiao
AU  - Pi R
FAU - Liu, Mei
AU  - Liu M
FAU - Wang, Tieqiao
AU  - Wang T
FAU - Zheng, Xueping
AU  - Zheng X
FAU - Liu, Meng
AU  - Liu M
FAU - Lin, Mingdong
AU  - Lin M
FAU - Liu, Peiqing
AU  - Liu P
FAU - Tao, Liang
AU  - Tao L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090402
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - FYY3R43WGO (Minocycline)
RN  - VB0R961HZT (Prednisone)
SB  - IM
EIN - J Neuroimmunol. 2009 Oct 30;215(1-2):130
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/genetics
MH  - Central Nervous System/drug effects/immunology/pathology
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects/immunology
MH  - Drug Therapy, Combination
MH  - Encephalomyelitis, Autoimmune, Experimental/*drug 
      therapy/immunology/physiopathology
MH  - Female
MH  - Immunosuppression Therapy/*methods
MH  - Magnetic Resonance Imaging
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Minocycline/*pharmacology/therapeutic use
MH  - Nerve Fibers, Myelinated/drug effects/immunology/pathology
MH  - Nerve Growth Factor/genetics
MH  - Prednisone/*pharmacology/therapeutic use
MH  - RNA, Messenger/drug effects/metabolism
MH  - Treatment Outcome
EDAT- 2009/04/07 09:00
MHDA- 2009/07/07 09:00
CRDT- 2009/04/07 09:00
PHST- 2008/12/22 00:00 [received]
PHST- 2009/02/13 00:00 [revised]
PHST- 2009/02/18 00:00 [accepted]
PHST- 2009/04/07 09:00 [entrez]
PHST- 2009/04/07 09:00 [pubmed]
PHST- 2009/07/07 09:00 [medline]
AID - S0165-5728(09)00070-8 [pii]
AID - 10.1016/j.jneuroim.2009.02.016 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2009 May 29;210(1-2):22-9. doi: 10.1016/j.jneuroim.2009.02.016. 
      Epub 2009 Apr 2.